Azacitidine/venetoclax reduced the risk of disease progression, relapse, or death by 39% compared with induction chemotherapy in AML patients, improving event-free ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD. In part 2 of an interview ...

Allo-HSCT significantly improved survival in real-world pediatric AML, with CR1 patients showing the best outcomes, achieving OS and DFS rates of 84.2% and 73.4%. Matched sibling and unrelated donors ...

AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...

The therapeutic arsenal for the management of AML has expanded significantly in recent years. Before 2017, newly diagnosed AML was treated with either standard cytarabine- and anthracycline-based ...

Your doctor can give you more information about your outlook (prognosis). For general information and support you can talk with the Cancer Research UK information nurses on freephone 0808 800 4040, ...

Adults and children can get AML, but it is most often diagnosed in older people. Chemotherapy is the main treatment, you might also have a bone marrow or stem cell transplant. Symptoms of AML can ...

The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...

Acute myeloid leukemia (AML) treatment side effects can include hair loss, fatigue, and nausea. However, these will vary depending on the type of treatment a person receives and how their cancer ...